Skip to content

Age of Blood in Sickle Cell Transfusion

Age of Blood in Sickle Cell Transfusion -The Effects of Phosphotidylserine Expression on Older Red Cell Units in Adults With Sickle Cell Disease

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03704922
Enrollment
26
Registered
2018-10-15
Start date
2017-10-04
Completion date
2024-01-11
Last updated
2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

Transfusion

Brief summary

The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD). To test this hypothesis, the study staff will perform a randomized prospective clinical trial. In aim 1, the study staff will determine the biochemical differences between ≥30 day-old versus ≤10 day-old units. In aim 2, the study staff will determine the physiologic effects of the transfused blood in a patient with SCD. Lastly, in aim 3, the study staff will explore the clinical implications of receiving older red cells over a 3 month period.

Detailed description

The Investigators assembled a multidisciplinary investigative team to examine the potential effects of older red cell units in adults with Sickle Cell Disease(SCD). Study staff have preliminary data that show: 1) there is equipoise among blood bank directors about the effects of older units in adults with SCD, 2) in our institution, many adults are administered older units, 3) older units activate macrophages and 4) this physiology promoted by older units is associated with an increased risk of infection. Our team is now poised to take the next investigative step: a prospective, randomized study. In Milwaukee, 1/3 of units transfused to adults with SCD are \>30 days old, but nation-wide some restrict the transfusion of older units. About four hundred adults receive care in the Adult Sickle Cell Clinic at Froedtert Hospital in Milwaukee, about 23 of who receive chronic outpatient transfusions for chronic pain or stroke prophylaxis. Transfusions are administered to adults regardless of storage age, except in the case of red cell exchange, for which there is a policy to use less than 14 day old units. In a 3-year retrospective review of transfusions administered to adults with SCD, 627 units were given via simple transfusion over 281 outpatient encounters. The overall median unit storage age was 22 days (range: 2-42 days), and 25% of the units transfused were stored 33 days or longer. To determine the opinions and policies of other hospital blood bank directors about the use of older red cell units for patients with SCD, study staff conducted a nation-wide survey (n=90). While only 23% of respondents had a storage age restriction policy for patients with SCD, 31% thought that older units were not as effective as younger units, and 65% believed that evidence-based policies were needed Adults with SCD may be susceptible to the effects of an older unit's physiology because they are prone to infection, inflamed, and poorly equipped to handle excess iron. In a cohort of 40 steady-state adults with SCD, the investigators specifically measured markers of inflammation and iron excess. High sensitivity C-reactive protein, a marker of systemic inflammation, was found to be markedly elevated (median 5.6 mg/L, range 0.4-60 mg/L; reference range \<1.0 mg/L), as was ferritin, a marker of iron stores (median 2,969 ng/ml, range 20-12,300 ng/ml; reference range 13-400 ng/ml). Forty chronically-transfused adults with SCD will be randomized in a double-blind fashion to receive ≥30 day-old or ≤10 day-old units for, at most, 3 consecutive outpatient transfusions. Subjects will be randomized in blocks of 5 and stratified by age: at least 10 subjects from each of the age ranges 16-30 and 31-60 years will be enrolled. Pre-transfusion, sterile samples will be extracted from red cell units. Patient peripheral blood will be also obtained 1 month before randomization, immediately pre-transfusion, and 2 and 24 hours post-transfusion. Hemoglobin will be measured pre-transfusion, 2 and 24 hours post-transfusion, and 2 weeks post transfusion. Participants will complete standardized diaries daily to document symptoms of infection, SCD pain, medications and Emergency Department(ED) or hospital use. Diaries will be collected and participants will be assessed with each transfusion encounter and 4 weeks after the last transfusion. To ensure compliance, coordinators will contact subjects weekly to complete the diaries. Study staff will evaluate red cells pre- and post-transfusion for Phosphatidylserine(PE), Phosphatidylethanolamine (PS), and microparticles as above for all blood samples. White cells will be isolated with established separation techniques. The white cell populations of interest will be defined by their location on a forward scatter/side scatter plot and their positivity using key fluorochrome-labeled identity markers (macrophages: CD14, neutrophils: CD16). Once the cell populations of interest are identified, the cells will be evaluated for various markers of activation. The plasma fraction from each patient and red cell unit will be diverted to determine concentrations of free heme/hemoglobin, cytokines, and NTBI, respectively.

Interventions

BIOLOGICALTransfusion

Red cell units for transfusion

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* age 16 to 60 years * have diagnosis of sickle cell disease * receiving outpatient red cell transfusion therapy * outpatient at the time of transfusion

Exclusion criteria

* history of reactions to transfusion therapy that cannot be adequately managed by antihistamines * do not have crossmatch compatible red cells * participation in another therapeutic trial for SCD * pregnant * HIV positive * uncontrolled inter-current illness, or psychiatric illness/social situations that would limit compliance with study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Biochemically Old Red Cell Unitsthrough third transfusion, an average of 18 weeksThe investigators will compare the transfusions provided to the two groups (the proportion of biochemically old units when stored ≥30 days compared to when stored ≤10 days) using a Fisher exact test at an alpha of 0.05.

Other

MeasureTime frameDescription
Change in the Concentration of CD62L Positive Circulating Monocytesthrough third transfusion, an average of 18 weeksChange in CD62Lcirculating monocyte/macrophage mean fluorescence intensity (MFI) at 2 hours post-transfusion compared to the subject pre-transfusion. The investigators will compare the two groups using a two sample two-sided t-test of the log at an alpha of 0.05. Power: In addition, we will use a generalized linear model to include biochemically old units transfused,regardless of unit age, as a covariate. Other co-variates will include free heme, cell free hemoglobin, and non-transferrin bound iron (NTBI) from the transfused unit. We will similarly compare secondary activation endpoints: activation markers for neutrophils and measured cytokine concentrations. When possible, donor and recipient red cells will be differentiated in S-antigen negative patients who are by chance provided S-positive heterozygous or homozygous donor red cells.
Percentage of Infections in Adultsthrough fourth transfusion, an average of 24 weeksThe primary endpoint is the percentage of infections in adults who receive ≥30 day-old units as compared to ≤10 day-old units. The presence of an indwelling catheter will be used as a key co-variate in this analysis. The investigators will further explore the relationship of blood age and transfusion of biochemically old red cell units on the change in hemoglobin (Hb) and hemoglobin S (HbS)% over time, daily pain scores, opioid use and dose, emergency department (ED) and hospitalization rate, infection symptoms, new alloantibody formation, and antibiotic use during the 3-month study period. The investigators will compare groups using a Fisher exact test. Power: A difference of 20% will be of clinical interest. The investigators do not expect to have adequate power for this pilot study but at an alpha of 0.05 with 20 subjects in each group the investigators will be able to detect a difference of 47% between the proportions.

Countries

United States

Participant flow

Participants by arm

ArmCount
≤10 Day Blood
Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events. Transfusion: Red cell units for transfusion
13
≥30 Day Blood
Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events. Transfusion: Red cell units for transfusion
13
Total26

Baseline characteristics

Characteristic≤10 Day BloodTotal≥30 Day Blood
Age, Continuous30.2 years
STANDARD_DEVIATION 8.5
30.0 years
STANDARD_DEVIATION 9.7
29.8 years
STANDARD_DEVIATION 11.2
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants26 Participants13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
13 Participants26 Participants13 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
United States
13 Participants26 Participants13 Participants
Sex: Female, Male
Female
6 Participants16 Participants10 Participants
Sex: Female, Male
Male
7 Participants10 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 13
other
Total, other adverse events
4 / 135 / 13
serious
Total, serious adverse events
3 / 135 / 13

Outcome results

Primary

Proportion of Biochemically Old Red Cell Units

The investigators will compare the transfusions provided to the two groups (the proportion of biochemically old units when stored ≥30 days compared to when stored ≤10 days) using a Fisher exact test at an alpha of 0.05.

Time frame: through third transfusion, an average of 18 weeks

ArmMeasureValue (NUMBER)
≤10 Day BloodProportion of Biochemically Old Red Cell Units0.71 proportion biologically old units
≥30 Day BloodProportion of Biochemically Old Red Cell Units0.86 proportion biologically old units
p-value: 0.051Fisher Exact
Other Pre-specified

Change in the Concentration of CD62L Positive Circulating Monocytes

Change in CD62Lcirculating monocyte/macrophage mean fluorescence intensity (MFI) at 2 hours post-transfusion compared to the subject pre-transfusion. The investigators will compare the two groups using a two sample two-sided t-test of the log at an alpha of 0.05. Power: In addition, we will use a generalized linear model to include biochemically old units transfused,regardless of unit age, as a covariate. Other co-variates will include free heme, cell free hemoglobin, and non-transferrin bound iron (NTBI) from the transfused unit. We will similarly compare secondary activation endpoints: activation markers for neutrophils and measured cytokine concentrations. When possible, donor and recipient red cells will be differentiated in S-antigen negative patients who are by chance provided S-positive heterozygous or homozygous donor red cells.

Time frame: through third transfusion, an average of 18 weeks

Other Pre-specified

Percentage of Infections in Adults

The primary endpoint is the percentage of infections in adults who receive ≥30 day-old units as compared to ≤10 day-old units. The presence of an indwelling catheter will be used as a key co-variate in this analysis. The investigators will further explore the relationship of blood age and transfusion of biochemically old red cell units on the change in hemoglobin (Hb) and hemoglobin S (HbS)% over time, daily pain scores, opioid use and dose, emergency department (ED) and hospitalization rate, infection symptoms, new alloantibody formation, and antibiotic use during the 3-month study period. The investigators will compare groups using a Fisher exact test. Power: A difference of 20% will be of clinical interest. The investigators do not expect to have adequate power for this pilot study but at an alpha of 0.05 with 20 subjects in each group the investigators will be able to detect a difference of 47% between the proportions.

Time frame: through fourth transfusion, an average of 24 weeks

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026